|  |
| --- |
| May 13, 2015 |
|  |
| Hans-Jörg Heims  Head of Corporate Press  Phone +49 201 177-3425  Fax +49 201 177-3030  hans-joerg.heims@evonik.com |
| Alexandra Boy  Deputy Head Corporate Press  Phone +49 201 177-3167  Fax +49 201 177-3030  alexandra.boy@evonik.com |
| Evonik Industries AG  Rellinghauser Straße 1-11  45128 Essen Germany  Phone +49 201 177-01  Telefax +49 201 177-3475  www.evonik.de  **Supervisory Board**  Dr. Werner Müller, Chairman  Executive Board  Dr. Klaus Engel, Chairman  Christian Kullmann  Thomas Wessel Patrik Wohlhauser Ute Wolf  Registered office Essen  Registered court  Essen local court  Commercial registry B 19474  VAT ID no. DE 811160003 |

**Evonik added to MSCI Indexes**

ESSEN. Shares of the specialty chemicals company Evonik Industries AG will be added to the Morgan Stanley Capital International (MSCI) World and Germany Indexes effective June 1, 2015. MSCI announced the results of the May 2015 Annual Index Review yesterday night. The inclusion follows the recent placements of shares by a major shareholder of Evonik.

MSCI offers a family of consistent and comparable indexes which comprise the world’s largest companies and are broadly used by investors around the world to develop and benchmark their global equity portfolios.

Ute Wolf, CFO of Evonik, comments: “Evonik’s inclusion to the MSCI Indexes enhances our presence in the most important indexes globally. This means greater visibility for Evonik at the international financial markets and will further increase the high level of interest from global investors in our share. Even more motivated by the MSCI inclusion, we will continue our capital market oriented approach and further intensify our dialogue with international investors.”

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders   
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2014 more than 33,000 employees generated sales of around €12.9 billion and an operating profit (adjusted EBITDA) of about €1.9 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.